Digirad (DRAD) Receives FDA 510(k) Clearance for nSPEED(R) Software
More News related to DRAD
- Digirad Corporation Reports Third Quarter 2009 Financial Results
- Trading Radar for 10/22: AT&T (T), McDonalds (MCD), Amazon.com (AMZN), 3M (MMM), Dow Chemical (DOW), UPS (UPS) Report
- Digirad Corporation to Present at BIOCOM 4th Annual Investor Conference
- Digirad Introduces c.pax(TM) for Cardiology
- Digirad Corporation to Release Third Quarter and Nine-Month Financial Results On October 22, 2009
More News related to FDA
- Hemispherx Biopharma (HEB) Reports a Q3 Loss; Comments on FDA Responses
- Wright Medical Group (WMGI) Announces FDA Approval For CONSERVE Plus Total Hip Resurfacing System
- Vascular Solutions (VASC) Receives 501(k) Clearance from U.S. FDA for GuideLiner Catheter
- Glaxo (GSK) and XenoPort (XNPT) Announed that U.S. FDA Has Extended the Review Date of GSK1838262/XP13512
- Compugen (CGEN) Announces Discovery of Biomarker CGEN-40001 for Type 2 Diabetes
Digirad Corporation (Nasdaq: DRAD) today announced it received from the U.S. FDA 510(k) clearance for its new nSPEED(R) reconstruction software -- for reduced imaging time and improved image quality with less radiation exposure for patients -- to be used in its imaging systems for SPECT procedures at either half-time and/or half count densities with parallel and non-parallel hole collimators.
Digirad Corporation provides diagnostic nuclear and ultrasound imaging systems and services to physicians' offices, hospitals, imaging centers, and other medical services providers primarily in the United States.
Related Categories
FDAStocks Mentioned
+0.07Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
